References
1. Lee HY, Walsh S and Creamer D.
Initial presentation of DRESS: often misdiagnosed as infections. Arch
Dermatol 2012;148:1085-7.
2. Cacoub P, Musette P, Descamps V,
Meyer O, Speirs C, Finzi L, et al. The DRESS syndrome: a literature
review. Am J Med 2011;124:588-97.
3. Kardaun S, Sekula P,
Valeyrie‐Allanore L, Liss Y, Chu C, Creamer D, et al. Drug reaction with
eosinophilia and systemic symptoms (DRESS): an original multisystem
adverse drug reaction. Results from the prospective RegiSCAR study. Br J
Dermatol 2013;169:1071-80.
4. Walsh S, Diaz‐Cano S, Higgins E,
Morris‐Jones R, Bashir S, Bernal W, et al. Drug reaction with
eosinophilia and systemic symptoms: is cutaneous phenotype a prognostic
marker for outcome? A review of clinicopathological features of 27
cases. Br J Dermatol 2013;168:391-401.
5. Chen Y-C, Chiu H-C and Chu C-Y.
Drug reaction with eosinophilia and systemic symptoms: a retrospective
study of 60 cases. Arch Dermatol 2010;146:1373-9.
6. Chen Y-C, Chang C-Y, Cho Y-T, Chiu
H-C and Chu C-Y. Long-term sequelae of drug reaction with eosinophilia
and systemic symptoms: a retrospective cohort study from Taiwan. J Am
Acad Dermatol 2013;68:459-65.
7. Tennis P and Stern RS. Risk of
serious cutaneous disorders after initiation of use of phenytoin,
carbamazepine, or sodium valproate: a record linkage study. J Neurol
1997;49:542-6.
8. Genin E, Chen D, Hung S, Sekula P,
Schumacher M, Chang P, et al. HLA-A* 31: 01 and different types of
carbamazepine-induced severe cutaneous adverse reactions: an
international study and meta-analysis. Pharmacogenomics J 2014;14:281.
9. Hung S-I, Chung W-H, Liou L-B, Chu
C-C, Lin M, Huang H-P, et al. HLA-B* 5801 allele as a genetic marker for
severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad
Sci U S A 2005;102:4134-9.
10. Chen W-T, Wang C-W, Lu C-W, Chen
C-B, Lee H-E, Hung S-I, et al. The function of HLA-B* 13: 01 involved in
the pathomechanism of dapsone-induced severe cutaneous adverse
reactions. J Investig Dermatol 2018;138:1546-54.
11. Lin C-H, Chen J-K, Ko T-M, Wei
C-Y, Wu J-Y, Chung W-H, et al. Immunologic basis for allopurinol-induced
severe cutaneous adverse reactions: HLA-B* 58: 01-restricted activation
of drug-specific T cells and molecular interaction. J Allergy Clin
Immunol 2015;135:1063-5. e5.
12. Takahashi R, Kano Y, Yamazaki Y,
Kimishima M, Mizukawa Y and Shiohara T. Defective regulatory T cells in
patients with severe drug eruptions: timing of the dysfunction is
associated with the pathological phenotype and outcome. J Immunol
2009;182:8071-9.
13. Picard D, Janela B, Descamps V,
D’incan M, Courville P, Jacquot S, et al. Drug reaction with
eosinophilia and systemic symptoms (DRESS): a multiorgan antiviral T
cell response. Sci Transl Med 2010;2:46ra62.
14. Tohyama M, Hashimoto K, Yasukawa
M, Kimura H, Horikawa T, Nakajima K, et al. Association of human
herpesvirus 6 reactivation with the flaring and severity of drug‐induced
hypersensitivity syndrome. Br J Dermatol 2007;157:934-40.
15. Kano Y, Hiraharas K, Sakuma K and
Shiohara T. Several herpesviruses can reactivate in a severe
drug‐induced multiorgan reaction in the same sequential order as in
graft‐versus‐host disease. Br J Dermatol 2006;155:301-6.
16. Asano Y, Kagawa H, Kano Y and
Shiohara T. Cytomegalovirus disease during severe drug eruptions: report
of 2 cases and retrospective study of 18 patients with drug-induced
hypersensitivity syndrome. Arch Dermatol 2009;145:1030-6.
17. Roujeau J-C and Dupin N. Virus
reactivation in drug reaction with eosinophilia and systemic symptoms
(DRESS) results from a strong drug-specific immune response. J Allergy
Clin Immunol Pract 2017;5:811-2.
18. Kardaun S, Sidoroff A,
Valeyrie‐Allanore L, Halevy S, Davidovici B, Mockenhaupt M, et al.
Variability in the clinical pattern of cutaneous side‐effects of drugs
with systemic symptoms: does a DRESS syndrome really exist? Br J
Dermatol 2007;156:609-11.
19. Eshki M, Allanore L, Musette P,
Milpied B, Grange A, Guillaume J-C, et al. Twelve-year analysis of
severe cases of drug reaction with eosinophilia and systemic symptoms: a
cause of unpredictable multiorgan failure. Arch Dermatol 2009;145:67-72.
20. Mardivirin L, Lacroix A,
Delebassée S, Descamps V and Ranger-Rogez S. Augmentation de la
réplication in vitro de l’herpèsvirus humain 6 en présence de valproate
de sodium. Virologie 2007;11:151-3.
21. Kuntz-Simon G and Obert G. Sodium
valproate, an anticonvulsant drug, stimulates human cytomegalovirus
replication. J Gen Virol 1995;76:1409-15.
22. Funck-Brentano E, Duong T-A,
Bouvresse S, Bagot M, Wolkenstein P, Roujeau J-C, et al. Therapeutic
management of DRESS: a retrospective study of 38 cases. J Am Acad
Dermatol 2015;72:246-52.
23. Shiohara T, Kano Y, Hirahara K
and Aoyama Y. Prediction and management of drug reaction with
eosinophilia and systemic symptoms (DRESS). Taylor & Francis, 2017.